Use of proton pump inhibitors and risk of osteoporosis-related fractures.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53

Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ (2012) 2.45

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med (2011) 2.27

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One (2011) 2.11

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int (2012) 1.76

Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology (2010) 1.55

Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol (2012) 1.43

Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int (2009) 1.38

CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med (2012) 1.26

Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep (2010) 1.23

Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res (2010) 1.21

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int (2010) 1.17

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med (2011) 1.16

Update on medications with adverse skeletal effects. Mayo Clin Proc (2011) 1.16

Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone (2009) 1.04

Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. Am J Gastroenterol (2016) 1.02

Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol (2009) 1.00

Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol (2012) 0.95

The risks of PPI therapy. Nat Rev Gastroenterol Hepatol (2012) 0.94

Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology (2009) 0.93

Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92

Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation. Osteoporos Int (2014) 0.89

Association of peptic ulcer disease and pulmonary disease with risk of periprosthetic fracture after primary total knee arthroplasty. Arthritis Care Res (Hoboken) (2011) 0.89

Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ (2008) 0.88

Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis (2014) 0.87

The role of the gastrointestinal tract in calcium homeostasis and bone remodeling. Osteoporos Int (2013) 0.85

Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep (2012) 0.84

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83

Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol (2013) 0.83

The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am (2010) 0.83

Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf (2013) 0.83

Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. Wien Med Wochenschr (2012) 0.82

Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res (2015) 0.82

Long-Term Alendronate Use Not without Consequences? Int J Rheumatol (2010) 0.82

A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver (2015) 0.81

Another bad break for proton-pump inhibitors? Nat Rev Rheumatol (2009) 0.81

Do proton pump inhibitors protect against cancer progression in GERD? Surg Today (2012) 0.81

Acute oxalate nephropathy associated with orlistat. J Nephropathol (2016) 0.80

Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. Acta Orthop (2012) 0.80

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 0.79

A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in Cats. J Vet Intern Med (2016) 0.79

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int (2011) 0.79

Increased Risk of Osteoporosis in Patients With Peptic Ulcer Disease: A Nationwide Population-Based Study. Medicine (Baltimore) (2016) 0.79

Dietary guideline adherence for gastroesophageal reflux disease. BMC Gastroenterol (2014) 0.79

Pantoprazole decreases cell viability and function of human osteoclasts in vitro. Mediators Inflamm (2015) 0.78

Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep (2013) 0.78

Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos Int (2016) 0.78

Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clin Epidemiol (2013) 0.78

[Pharmacogenic osteoporosis beyond cortisone. Proton pump inhibitors, glitazones and diuretics]. Z Rheumatol (2014) 0.78

How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs (2016) 0.77

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol (2010) 0.77

A close look at acid reflux drugs points to possible risks. Nat Med (2009) 0.77

Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. J Bone Miner Metab (2010) 0.76

Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med (2015) 0.76

Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int (2013) 0.76

Does laryngopharyngeal reflux cause intraoral burning sensations? A preliminary study. Eur Arch Otorhinolaryngol (2011) 0.76

Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure. Hepat Mon (2014) 0.76

Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. Can J Gastroenterol (2013) 0.75

Chemoprevention in Barrett's esophagus: are we there yet, are we there yet...? Clin Gastroenterol Hepatol (2009) 0.75

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem? Clin Med Insights Gastroenterol (2012) 0.75

Examining the potential relationship between proton pump inhibitor use and the risk of bone fracture. Gastroenterol Hepatol (N Y) (2011) 0.75

The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol (2012) 0.75

Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspective. J Am Assoc Nurse Pract (2014) 0.75

Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop (2015) 0.75

Calcium revisited: part I. Bonekey Rep (2013) 0.75

Proton pump inhibitors and osteoporosis-related fractures. CMAJ (2009) 0.75

Balancing the risks and benefits of proton pump inhibitors. Ann Fam Med (2011) 0.75

Risk of fracture and pneumonia from acid suppressive drugs. World J Methodol (2011) 0.75

Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model. Biomed Rep (2016) 0.75

Prescribing patterns and economic costs of proton pump inhibitors in Colombia. Colomb Med (Cali) (2013) 0.75

Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol (2017) 0.75

Drug utilization patterns among elderly hospitalized patients on poly-pharmacy in Punjab, Pakistan. J Pharm Policy Pract (2017) 0.75

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Adv Ther (2017) 0.75

From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis. Dig Dis Sci (2017) 0.75

Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study. Aliment Pharmacol Ther (2017) 0.75

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1995) 13.01

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05

Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA (2005) 6.87

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2004) 6.06

Assessment of fracture risk. Osteoporos Int (2004) 5.15

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA (2001) 5.09

Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75

Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68

Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc (1993) 3.55

Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA (2001) 3.13

Current and projected rates of hip fracture in Canada. CMAJ (1997) 2.85

Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33

The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32

Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1998) 2.22

Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17

An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest (1984) 1.76

Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int (1993) 1.72

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther (2006) 1.70

Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust (2000) 1.62

Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab (2006) 1.39

Who is using chronic acid suppression therapy and why? Am J Gastroenterol (2003) 1.34

Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med (1997) 1.30

The absorption of calcium carbonate. Ann Intern Med (1967) 1.29

Establishing a population data-based policy unit. Med Care (1999) 1.25

Step-down management of gastroesophageal reflux disease. Gastroenterology (2001) 1.20

Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med (1987) 1.19

Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev (2004) 1.18

Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13

Alcohol intake and its relationship with bone mineral density, falls, and fracture risk in older men. J Am Geriatr Soc (2006) 1.11

Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin (2007) 0.95

Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev (2003) 0.95

Clinical risk factors for fracture in postmenopausal Canadian women: a population-based prevalence study. Bone (2006) 0.90

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48

Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res (2011) 2.24

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24

Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res (2012) 2.22

Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases. J Clin Epidemiol (2008) 2.19

AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology (2003) 2.17

Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15

Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol (2008) 2.04

The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92

Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res (2010) 1.90

Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86

FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res (2012) 1.82

Low bone mineral density and fracture burden in postmenopausal women. CMAJ (2007) 1.81

The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology (2008) 1.79

Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma. J Allergy Clin Immunol (2008) 1.78

Biphasic fracture risk in diabetes: a population-based study. Bone (2007) 1.68

Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res (2011) 1.68

Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ (2008) 1.65

Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab (2012) 1.61

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology (2009) 1.59

Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med (2016) 1.56

A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56

WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55

A before-and-after study of fracture risk reporting and osteoporosis treatment initiation. Ann Intern Med (2010) 1.51

Outcomes among 3.5 million newly diagnosed hypertensive Canadians. Can J Cardiol (2013) 1.50

Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol (2003) 1.48

Therapy insight: Osteoporosis in inflammatory bowel disease--advances and retreats. Nat Clin Pract Gastroenterol Hepatol (2005) 1.48

Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ (2010) 1.45

Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res (2006) 1.45

The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol (2013) 1.44

Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res (2011) 1.39

Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab (2006) 1.39

Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. Can Assoc Radiol J (2007) 1.32

FRAX(®) with and without bone mineral density. Calcif Tissue Int (2011) 1.29

Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28

Canadian Aboriginal women have a higher prevalence of vitamin D deficiency than non-Aboriginal women despite similar dietary vitamin D intakes. J Nutr (2007) 1.27

10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med (2008) 1.20

Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18

The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol (2003) 1.17

Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol (2013) 1.17

The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol (2009) 1.15

Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom (2007) 1.15

Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res (2009) 1.13

Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health (2012) 1.11

Postfracture care for older women: gaps between optimal care and actual care. Can Fam Physician (2008) 1.11

Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11

Socioeconomic status and the utilization of diagnostic imaging in an urban setting. CMAJ (2005) 1.09

Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol (2009) 1.09

A generally robust approach for testing hypotheses and setting confidence intervals for effect sizes. Psychol Methods (2008) 1.07

Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program. Bone (2008) 1.07

Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging. J Nucl Med (2005) 1.07

Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler (2012) 1.07

Fracture risk in living kidney donors: a matched cohort study. Am J Kidney Dis (2012) 1.06

Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children. CMAJ (2004) 1.06

The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology (2012) 1.05

Adjusting fracture probability by trabecular bone score. Calcif Tissue Int (2015) 1.04

Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care (2007) 1.04

Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res (2010) 1.04

Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med (2007) 1.02

Striatal function in generalized social phobia: a functional magnetic resonance imaging study. Biol Psychiatry (2006) 1.02

Parents bereaved by offspring suicide: a population-based longitudinal case-control study. JAMA Psychiatry (2013) 1.01

Bone scan findings in metastatic calcification from calciphylaxis. Clin Nucl Med (2008) 1.01

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom (2011) 1.00

Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab (2013) 0.99

Surveillance of ischemic heart disease should include physician billing claims: population-based evidence from administrative health data across seven Canadian provinces. BMC Cardiovasc Disord (2013) 0.97

Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm Bowel Dis (2005) 0.97

Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol (2014) 0.96

Fracture risk among First Nations people: a retrospective matched cohort study. CMAJ (2004) 0.96

Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol (2011) 0.96

Identifying reprioritization response shift in a stroke caregiver population: a comparison of missing data methods. Qual Life Res (2014) 0.96

Direct costs of fractures in Canada and trends 1996-2006: a population-based cost-of-illness analysis. J Bone Miner Res (2011) 0.95

Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation (2003) 0.94

Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol (2011) 0.94

Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis. Clin Nucl Med (2011) 0.94

Ethnic and regional differences in prevalence and correlates of chronic diseases and risk factors in northern Canada. Prev Chronic Dis (2009) 0.94

Number of osteoporotic sites and fracture risk assessment: a cohort study from the Manitoba Bone Density Program. J Bone Miner Res (2007) 0.94

Response shift was identified over multiple occasions with a structural equation modeling framework. J Clin Epidemiol (2009) 0.93

Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol (2008) 0.93

Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Res Treat (2010) 0.93

Inflammatory bowel disease and the risk of fracture after controlling for FRAX. J Bone Miner Res (2013) 0.93

The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol (2007) 0.93

Prognostic value of lung sestamibi uptake in myocardial perfusion imaging of patients with known or suspected coronary artery disease. J Am Coll Cardiol (2005) 0.91